Inmune Bio Inc. shares rise 3.15% premarket after ABIVAX Société Anonyme reports positive Phase III ABTECT-1 Induction trial results.

jueves, 24 de julio de 2025, 5:26 am ET1 min de lectura
INMB--
Inmune Bio Inc. rose 3.15% in premarket trading, with the company's recent news event being the ABIVAX Société Anonyme's shareholder/analyst call, where they announced positive top line results of the Phase III ABTECT-1 Induction trials.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios